Navigation Links
American Urological Association (AUA) Clinical Guidelines Recognizes Cryotherapy as Treatment Option for Prostate Cancer Patients

The New Best Practice Statements Were Presented at the AUA Annual Meeting Being Held in Orlando, Florida

YOKNEAM, Israel and PLYMOUTH MEETING, Pennsylvania, May 21 /PRNewswire/ -- Galil Medical, a global leader in cryotherapy, announced today that the American Urological Association has introduced clinical guidelines with best practice statements for prostate cryotherapy. The guidelines state that cryoablation is a treatment option for men with clinically confined prostate cancer of any grade and that salvage cryoablation is a treatment option in men who have failed radiation therapy.

Prostate cryotherapy uses extreme cold to freeze and destroy prostate cancer cells. This minimally invasive procedure is routinely and successfully performed on prostate cancer patients with varying disease stages as well as those who have failed radiation treatment. Prostate cancer is the most common cancer, other than skin cancers, in American men. The American Cancer Society estimates that during 2008 about 186,320 new cases of prostate cancer will be diagnosed in the United States.

The American Urological Association (AUA), the premier professional association for the advancement of urologic patient care, routinely adopts clinical guidelines and best practice statements, releasing updates as technology improves. Dr. Richard Babaian, Professor and Senior Medical Director at the MD Anderson Physician Network, presented the new guidelines for cryotherapy for the treatment of localized prostate cancer at the plenary session of the AUA annual meeting.

Martin J. Emerson, Galil Medical President and CEO comments, "We are pleased that the AUA, in its preeminent role in assessing new treatment options for urologists and their patients, now recognizes cryotherapy as a mainstream treatment option for patients diagnosed with localized prostate cancer."

Urologists can learn first-hand about cryotherapy at the Cryosurgical Ablation of the Prostate course being presented during the AUA annual meeting on Thursday, May 22, 2008 from 6-8 a.m.

A recently published retrospective study of primary prostate cryotherapy by Dr. Jeffrey Cohen reported 10-year follow up data with biochemical control comparable to external beam radiotherapy or prostate brachytherapy. The literature has also shown that advances over the last 10 years in cryoablation techniques have dramatically improved the morbidity profile.

New guidelines for the treatment of localized prostate cancer were released by the AUA in 2007 and emphasized communication with the patient regarding risk, treatment options, and potential outcomes. At that time, it was recognized that cryotherapy for the treatment of localized prostate cancer should be the topic of an AUA best practice policy.

About Galil Medical

Galil Medical develops, manufactures and markets innovative products utilizing a proprietary cryotherapy platform that incorporates powerful freezing technology and revolutionary 17-gauge cryoablation needle design. Galil Medical systems enable minimally invasive, targeted ablation of benign and cancerous tumors while ensuring rapid recovery and enhanced quality of life for patients. The Presice(TM) Cryoablation System features multi-point thermal sensors (MTS) and advanced IceVue(TM) planning software for excellent procedure control in treating prostate and renal cancer. The SeedNet(TM) system provides physicians with an easy-to-use cryoablation solution to precisely ablate tumors while protecting adjacent structures.

Galil Medical is a global medical device company with offices in Yokneam, Israel; Plymouth Meeting, Pennsylvania; and London, Shareholders include Thomas, McNerney & Partners, The Vertical Group, Investor Growth Capital, Elron Electronic Industries Ltd. (NASDAQ:ELRN) and RDC Rafael Development Corporation, Ltd. For more information, please visit


"Galil Medical has received approval from Elron Electronic Industries Ltd. (NASDAQ: ELRN) to have the announcement associated with its ticker. Please associate this announcement also to the ELRN ticker."


Pam Schwartz

Communications Manager

Galil Medical

T: +972-4-909-3273

M: +972-52-625-4443

F: +972-4-959-1077

SOURCE Galil Medical Ltd
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Coalition for Pulmonary Fibrosis and American Thoracic Society Continue Research Partnership Through 2010
2. Elseviers Engineering Village Search Platform Combines the American Geological Institutes Georef Database With Google Maps
3. American Oriental Bioengineering Forms Science and Technology Advisory Committee
4. Bayer and Onyx Announce Nexavar Data Presentations at 44th American Society of Clinical Oncology Annual Meeting
5. Forest Laboratories, Inc. and Laboratorios Almirall, S.A. to Host Webcast to Discuss Aclidinium Bromide Data Presentations at the American Thoracic Society Annual Congress
6. Depth of MedImmunes Respiratory Disease Research Program Highlighted at Annual Meeting of the American Thoracic Society
7. American Oriental Bioengineering Comments on Earthquake
8. Moffitt Cancer Center Joins National Campaign To Implore Americans To Donate $1 To Accelerate Cancer Research
9. American Oriental Bioengineering Reports First Quarter 2008 Financial Results
10. LifeQuest World Launches Immune System Boosting Supplement to the North American Market
11. American Psychiatric Foundation Announces Recipients of 2008 Awards for Advancing Minority Mental Health
Post Your Comments:
(Date:11/26/2015)... MUMBAI , November 26, 2015 ... --> Accutest Research ... accredited Contract Research Organization (CRO), has ... Chase Cancer Center - Temple Health ... ,     (Photo: ) ...
(Date:11/25/2015)... --> ... 2020 report analyzes that automating biobanking workflow will ... long-term samples, minimizing manual errors, improving the workflow ... errors such as mislabeling or inaccurate sample barcoding ... a vital role in blood fractionation, DNA extraction, ...
(Date:11/25/2015)... 25, 2015 2 nouvelles études permettent ... les différences entre les souches bactériennes retrouvées dans la ... des êtres humains . Ces recherches  ouvrent une nouvelle ... prise en charge efficace de l,un des problèmes ... chats .    --> 2 nouvelles études ...
(Date:11/25/2015)... HOLLISTON, Mass. , Nov. 25, 2015 /PRNewswire/ ... ), a biotechnology company developing bioengineered organ implants for ... will present at the LD Micro "Main Event" ... p.m. PT. The presentation will be webcast live and ... will also be available at the conference for one-on-one ...
Breaking Biology Technology:
(Date:11/9/2015)...  Synaptics Inc. (NASDAQ: SYNA ), the leading ... into the automotive market with a comprehensive and dedicated ... consumer electronics human interface innovation. Synaptics, industry-leading touch controllers, ... automotive industry and will be implemented in numerous locations ... , Japan , and ...
(Date:10/29/2015)... Oct. 29, 2015  The J. Craig Venter Institute ... "DNA Synthesis and Biosecurity: Lessons Learned and Options for ... Health and Human Services guidance for synthetic biology providers ... --> --> Synthetic ... the potential to pose unique biosecurity threats. It now ...
(Date:10/29/2015)... NXTD ) ("NXT-ID" or ... the growing mobile commerce market and creator of ... leading marketplace to discover and buy innovative technology ... on StackSocial for this holiday season.   ... a biometric authentication company focused on the growing ...
Breaking Biology News(10 mins):